Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
about
Evaluation of Classifier Performance for Multiclass Phenotype Discrimination in Untargeted Metabolomics.Chromatographic determination of some biomarkers of liver cirrhosis and hepatocellular carcinoma in Egyptian patients.Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy.Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells.Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues.Metabolic reprogramming during hepatitis B disease progression offers novel diagnostic and therapeutic opportunities.Peiminine inhibits colorectal cancer cell proliferation by inducing apoptosis and autophagy and modulating key metabolic pathways.Disease monitoring of hepatocellular carcinoma through metabolomics.Differential metabonomic profiles of primary hepatocellular carcinoma tumors from alcoholic liver disease, HBV-infected, and HCV-infected cirrhotic patients.A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients.Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach.Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer.Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients.Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis.Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients.Monitoring clinical progression with mitochondrial disease biomarkers.Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation.Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation.Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease.Vitamin C in Cancer: A Metabolomics Perspective.Metabolomic analysis of serum from rats following long-term intake of Chinese sausage.High Expression of Glycolytic Genes in Cirrhosis Correlates With the Risk of Developing Liver Cancer
P2860
Q33844995-D913D69C-97C2-4DB6-B0E2-D48350D01CF7Q36197829-EE069256-B091-464E-8466-57F962C0106CQ36411014-68CBF858-9BAF-49E2-B4AB-F3D6E213BAB2Q37598554-FC255FDA-8CF2-4FE0-BAFE-63CDD796B5D6Q37738005-2847C348-BB8C-497C-A1DA-C5839FE7B884Q38157135-95ED5BB3-A506-4473-AFC5-B5A4ACD82AC4Q38703815-65EDBDB8-6E74-46DF-8218-FE8B2352E79AQ38768256-8D39C589-8BFE-4B31-A4B3-7535510D9CD4Q40053156-1833575C-F86C-4E77-AB11-6063632B7885Q40056735-C83A0F7A-F21A-4890-8E3B-86B1F3D1E6D2Q41200837-30F74E96-264D-4486-BE5F-95D3B0AF1D26Q41607194-047C3640-7B9E-4FD2-81FE-6974DACC6BA6Q41921666-B69068B1-4906-4D7F-810A-9F40A2026B12Q41926352-F30BA329-A791-4512-8489-84E775FC9847Q42252917-80612964-8B07-4F5F-87F6-02F3B7073C0DQ47098813-215A6BE4-36BA-4A89-8D22-576CDCD2DBBBQ47713915-DA496F3A-29DF-4533-BD05-907F403822DFQ49735252-9CC8EF6B-34FB-4BA1-B4D5-DD4C7C458641Q52564715-35C33A4E-EE25-4873-B911-D5E2395594DEQ52620439-0C60D19A-9F43-4B33-9E91-55C1388C0EBEQ55441110-FBD64AEE-D2DB-4F76-8462-0F654D6194B2Q55669702-115FBF3E-9617-41D3-B498-7F26276018A1Q59133582-F3236E1F-75F7-4A9B-993F-8729326E8B4F
P2860
Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@ast
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@en
type
label
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@ast
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@en
prefLabel
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@ast
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Serum Metabolomics to Identify ...... s to Hepatocellular Carcinoma.
@en
P2093
Chengjin Hu
Chunlei Fan
Fangting Dong
Huiguo Ding
Jianhua Cheng
Xianzhong Yan
Xiaofeng Shi
P2860
P2888
P356
10.1038/SREP18175
P407
P577
2015-12-10T00:00:00Z